Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone847-871-0377
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.57 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date6/20/2019 (Estimated)
OptionableNot Optionable
Aptinyx (NASDAQ:APTX) Frequently Asked Questions
What is Aptinyx's stock symbol?
Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How were Aptinyx's earnings last quarter?
Aptinyx Inc (NASDAQ:APTX) posted its earnings results on Thursday, March, 21st. The company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.12. The firm had revenue of $1.04 million for the quarter, compared to analyst estimates of $1.10 million. View Aptinyx's Earnings History.
When is Aptinyx's next earnings date?
What price target have analysts set for APTX?
5 brokers have issued 12 month target prices for Aptinyx's stock. Their predictions range from $8.00 to $22.00. On average, they expect Aptinyx's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 244.0% from the stock's current price. View Analyst Price Targets for Aptinyx.
What is the consensus analysts' recommendation for Aptinyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.
What are Wall Street analysts saying about Aptinyx stock?
Here are some recent quotes from research analysts about Aptinyx stock:
- 1. According to Zacks Investment Research, "Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. " (3/19/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and 12-month PT of $40 on APTX. With an initial focus on large indications within chronic pain, there are multiple other nervous system disorder oppys for the company’s candidates with better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models looks promising and important POC trial data will emerge in pain indications The Disclosure Section may be found on pages 4 – 5.in 1H19, which we believe has a above-average PoS and will significantly move the stock." (1/16/2019)
Has Aptinyx been receiving favorable news coverage?
News articles about APTX stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next few days.
Who are some of Aptinyx's key competitors?
Some companies that are related to Aptinyx include NuCana (NCNA), ProQR Therapeutics (PRQR), Obseva (OBSV), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), Odonate Therapeutics (ODT), GlycoMimetics (GLYC), ZEALAND PHARMA/S (ZEAL), ChemoCentryx (CCXI), Dermira (DERM), Stemline Therapeutics (STML), G1 Therapeutics (GTHX), Basilea Pharmaceutica (BPMUF), Prothena (PRTA) and Arcus Biosciences (RCUS).
What other stocks do shareholders of Aptinyx own?
Who are Aptinyx's key executives?
Aptinyx's management team includes the folowing people:
- Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
- Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
- Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 52)
- Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
- Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)
When did Aptinyx IPO?
(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Who are Aptinyx's major shareholders?
Aptinyx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Partner Fund Management L.P. (5.53%), BlackRock Inc. (3.45%), Victory Capital Management Inc. (1.99%), Geode Capital Management LLC (0.32%), Geode Capital Management LLC (0.32%) and Partner Investment Management L.P. (0.18%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.
Which major investors are selling Aptinyx stock?
Which major investors are buying Aptinyx stock?
APTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Partner Fund Management L.P., Geode Capital Management LLC, Geode Capital Management LLC, Millennium Management LLC, Virtus ETF Advisers LLC, New York State Common Retirement Fund and Bank of America Corp DE. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.
How do I buy shares of Aptinyx?
Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptinyx's stock price today?
One share of APTX stock can currently be purchased for approximately $4.36.
How big of a company is Aptinyx?
Aptinyx has a market capitalization of $146.06 million and generates $6.57 million in revenue each year. The company earns $-32,060,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.
What is Aptinyx's official website?
How can I contact Aptinyx?
Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]
MarketBeat Community Rating for Aptinyx (NASDAQ APTX)
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
